Compare Novartis with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PIRAMAL ENTERPRISES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PIRAMAL ENTERPRISES NOVARTIS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 513.2 17.0 3,023.0% View Chart
P/BV x 28.8 1.1 2,550.7% View Chart
Dividend Yield % 1.5 1.6 97.7%  

Financials

 NOVARTIS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    NOVARTIS
Mar-19
PIRAMAL ENTERPRISES
Mar-19
NOVARTIS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs9803,303 29.7%   
Low Rs6001,797 33.4%   
Sales per share (Unadj.) Rs198.7716.5 27.7%  
Earnings per share (Unadj.) Rs21.079.7 26.3%  
Cash flow per share (Unadj.) Rs22.3107.9 20.6%  
Dividends per share (Unadj.) Rs10.0028.00 35.7%  
Dividend yield (eoy) %1.31.1 115.3%  
Book value per share (Unadj.) Rs307.51,477.5 20.8%  
Shares outstanding (eoy) m24.69184.45 13.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.03.6 111.7%   
Avg P/E ratio x37.732.0 117.8%  
P/CF ratio (eoy) x35.523.6 150.2%  
Price / Book Value ratio x2.61.7 148.9%  
Dividend payout %47.735.1 135.8%   
Avg Mkt Cap Rs m19,508470,292 4.1%   
No. of employees `0000.67.8 7.4%   
Total wages/salary Rs m1,17122,504 5.2%   
Avg. sales/employee Rs Th8,445.416,899.4 50.0%   
Avg. wages/employee Rs Th2,015.72,877.7 70.0%   
Avg. net profit/employee Rs Th891.01,879.9 47.4%   
INCOME DATA
Net Sales Rs m4,907132,153 3.7%  
Other income Rs m7833,128 25.0%   
Total revenues Rs m5,689135,281 4.2%   
Gross profit Rs m12366,290 0.2%  
Depreciation Rs m325,202 0.6%   
Interest Rs m1644,097 0.0%   
Profit before tax Rs m85820,119 4.3%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3408,611 3.9%   
Profit after tax Rs m51814,701 3.5%  
Gross profit margin %2.550.2 5.0%  
Effective tax rate %39.642.8 92.6%   
Net profit margin %10.611.1 94.8%  
BALANCE SHEET DATA
Current assets Rs m8,055122,742 6.6%   
Current liabilities Rs m1,850310,810 0.6%   
Net working cap to sales %126.4-142.3 -88.9%  
Current ratio x4.40.4 1,102.4%  
Inventory Days Days4523 195.1%  
Debtors Days Days3439 87.3%  
Net fixed assets Rs m150116,904 0.1%   
Share capital Rs m123369 33.5%   
"Free" reserves Rs m7,469272,161 2.7%   
Net worth Rs m7,592272,530 2.8%   
Long term debt Rs m0270,196 0.0%   
Total assets Rs m9,824856,261 1.1%  
Interest coverage x54.91.5 3,773.0%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.50.2 323.6%   
Return on assets %5.46.9 79.1%  
Return on equity %6.85.4 126.4%  
Return on capital %11.512.4 92.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5815,200 0.4%   
Fx outflow Rs m1,3264,889 27.1%   
Net fx Rs m-1,26910,312 -12.3%   
CASH FLOW
From Operations Rs m-1,943-115,975 1.7%  
From Investments Rs m2,742-8,265 -33.2%  
From Financial Activity Rs m-298107,525 -0.3%  
Net Cashflow Rs m501-16,650 -3.0%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.0 50.0%  
FIIs % 1.6 26.6 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 16.5 130.3%  
Shareholders   41,647 93,274 44.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 11, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - SUVEN LIFESCIENCES COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS